The mean steady-state serum ADA concentrations observed in the combined analysis of the two studies were 8–10 μg/mL, identical to that observed in patients with CD, UC, RA, and PS under the same initial and maintenance dose [61]. This evidence concerns the gene ADA and rheumatoid arthritis.